Table 1

Characteristics of cohort by presence of fixed airflow obstruction (GOLD/ATS/ERS standard)

Cohort (n = 9573)


No fixed obstruction

Fixed obstruction

p value

Characteristic*

(FEV1/FVC > 0.70)

(FEV1/FVC ≤ 0.70)


Subjects, n

5009

4564

Male, n (%)

4567 (91)

4435 (97)

<0.001

Age, years

59 (14)

66 (11)

<0.001

Body Mass Index, n (%)

<0.001

15-18.5

29 (0.6)

135 (3.0)

18.5-25

714 (14)

1352 (30)

25-30

1664 (33)

1654 (36)

30-55

2602 (52)

1423 (31)

Comorbidities, n (%)

Hypertension

2667 (53)

2402 (53)

0.55

Diabetes

1174 (23)

792 (17)

<0.001

Congestive heart failure

533 (11)

517 (11)

0.28

Myocardial infarction

101 (2)

113 (2.5)

0.13

Atrial fibrillation

504 (10)

496 (11)

0.20

Depression

1176 (23)

858 (19)

<0.001

Schizophrenia

92 (1.8)

85 (1.9)

0.93

Smoking status, n (%)

<0.001

Never/Former

3616 (72)

2633 (58)

Current

1393 (28)

1931 (42)

FEV1, L, mean (SD)

2.74 (0.81)

1.74 (0.74)

<0.001

FEV1, % predicted, mean (SD)

80 (40)

54 (19)

<0.001

Severity of airflow limitation (FEV1, % predicted), n (%)

GOLD I: Mild (≥80%)

-

458 (10)

GOLD II: Moderate (50%-79%)

-

2202 (48)

GOLD III: Severe (30%-49%)

-

1362 (30)

GOLD IV: Very severe (<30%)

-

541 (12)

Number of albuterol MDI, n (%)

0

2925 (58)

1789 (39)

1-5

1053 (21)

872 (19)

6+

1031 (21)

1903 (42)

Number of ipratroprium MDI, n (%)

<0.001

0

3936 (79)

2086 (46)

1-2

159 (3)

219 (5)

3+

914 (18)

2259 (50)


*Numbers represent mean (SD) unless otherwise noted.

FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; MDI, metered dose inhaler.

Cooke et al. BMC Health Services Research 2011 11:37   doi:10.1186/1472-6963-11-37

Open Data